English | Español

Amgen Inc.
Press release submission | Dec 20, 2021

FDA Approves Otezla® (Apremilast) for the Treatment of Adult Patients With Plaque Psoriasis, Regardless of Severity Level

Press release submission | Sep 5, 2021

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
Press release submission | Mar 15, 2019

AMGEN, INC.: Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Carol Ostrow | Dec 15, 2017

Amgen Foundation commits $500,000 to help southern California wildfire victims
Carol Ostrow | Dec 10, 2017

Amgen's Repatha wins FDA approval
Carol Ostrow | Dec 8, 2017

Amgen presents at Evercore conference
Mark Iandolo | Nov 1, 2017

Cancer information awareness campaign features conversations with Joan Lunden
Kathy Adams | Oct 22, 2017

Amgen, Boston Children's Hospital team up for study on unusual pain response

Trending
+ Pharmaceuticals
Patient Daily | Jun 18, 2025

ENT specialist on acid reflux: ‘You actually have a structural issue that may predispose you to sinusitis’
+ Pharmaceuticals
Patient Daily | Jun 23, 2025

PhRMA says patients in the U.S. face higher prescription costs due to 340B program
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

FDA loophole lets low-quality drugs from China and India flood U.S. market, while American manufacturers are held to higher standards